AUROBINDO PHARMA (AUROPHARMA) - Live BSE, NSE Stock Quotes - AUROBINDO PHARMA Analysis Update - Equitymaster.com
X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2016 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA   (AUBD)

REFRESH
Live BSE Quotes Sep 29, 2016 (Close)
Price (Rs)825.05 Open (Rs) 874.90 High (Rs) 879.00 Low (Rs) 782.00
% Change-4.98 Volume 309,538 Value (Rs) 258,286,704 52-Week H/L 891.50 / 582.00
Live NSE Quotes Sep 29, 2016 (Close)
Price (Rs)825.25 Open (Rs) 876.00 High (Rs) 876.50 Low (Rs) 784.35
% Change-5.07 Volume 4,591,243 Value (Rs) 3,835,629,336 52-Week H/L 891.50 / 582.00
Valuation
EPS (Rs)* 37.19 P/E Ratio (x) 22.18 Market Cap (Rs m) 480,938.15 P/BV (x) 6.82
  *Trailing 12 months earnings, excluding extraordinary / exceptional items. BSE Sensex | CNX Nifty

Charts
AUROBINDO PHARMA Stock Price Chart (Rs) - 1 Year
Loading...
 
Peer Group:
Quote & Graph
     
 S&P BSE SENSEX 
PERIOD
Advanced Charts new

Related Views On News

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: US Segment Shows Signs of Improvement (Quarterly Results Update - Detailed)

Sep 12, 2016

Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Are You Ready for the 2017 Recession?(Vivek Kaul's Diary)

Sep 17, 2016

Sooner or later, the recovery myth will explode...

Buffett Owes His US$67 Billion Net Worth to These Three Words(The 5 Minute Wrapup)

Sep 22, 2016

The three words that made the biggest contribution to Warren Buffett's enormous wealth.

Asset Quality of PSBs Still Below Par(Chart Of The Day)

Sep 17, 2016

Structured Debt Restructuring not a cakewalk for banks.

Trading Nightmares(Daily Profit Hunter)

Sep 16, 2016

Asad Dossani discusses an experience that helped him control his emotions while trading. It takes years of hard work, but over time you can reduce your emotional reaction to trading losses. This improves your performance and reduces the stress you often experience as a trader

Should You Worry About How Much Your Fund Manager Earns?(Outside View)

Sep 19, 2016

PersonalFN explains why instead of focusing merely on how much your fund manager earns, a holistic assessment is imperative to select mutual funds prudently for your investment portfolio.

More

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

Detailed Financial Information With Charts

COMPARE AUROBINDO PHARMA WITH

MARKET STATS